Other examples of available anticancer agents that have been identified to exhibit potent anti-glioma effect at preclinical level include plicamycin an antineoplastic antibiotic agent [148,151], trametinib a MEK inhibitor [152,153], afatinib an EGFR inhibitor and topotecan a topoisomerase-I inhibitor [105]. Here, MAP2K7 is linked to central nervous system cancer.